|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter, unit** | **Rollover (Treatment During Double-blind Study)** | | | | | | | | | | **De Novo** | | | **All Participants** | | |
| **Placebo** | | | | **RBP-7000** **90 mg** | | | **RBP-7000** **120 mg** | | |
| **N** | **Mean**  **Change** | **SD** | **n** | | **Mean**  **Change** | **SD** | **n** | **Mean**  **Change** | **SD** | **n** | **Mean**  **Change** | **SD** | **n** | **Mean**  **Change** | **SD** |
| Metabolic parameters | | | | | | | | | | | | | | | | |
| Weight,b kg | 21 | 0.2 | 5.4 | 28 | | -1.5 | 5.8 | 30 | 0.7 | 5.0 | 338 | 2.1 | 7.8 | 417 | 1.7 | 7.5 |
| BMI,b kg/m2 | 21 | -0.04 | 2.05 | 28 | | -0.42 | 1.99 | 30 | 0.20 | 1.64 | 338 | 0.71 | 2.66 | 417 | 0.60 | 2.54 |
| Abdominal fat, waist-to-hip ratio | 21 | 0.01 | 0.08 | 29 | | -0.03 | 0.06 | 30 | 0.01 | 0.04 | 335 | 0.01 | 0.08 | 415 | 0.01 | 0.08 |
| Glucose, mg/dL | 21 | 5.3 | 19.1 | 28 | | -1.2 | 34.5 | 30 | 2.1 | 14.1 | 340 | 6.9 | 30.3 | 419 | 6.0 | 29.3 |
| HbA1c, % | 21 | 0.00 | 0.25 | 27 | | -0.03 | 0.59 | 29 | 0.01 | 0.24 | 344 | 0.13 | 0.49 | 421 | 0.11 | 0.47 |
| Cholesterol, mg/dL | 21 | -3.0 | 31.1 | 28 | | -8.5 | 31.3 | 30 | -9.5 | 29.5 | 341 | 0.9 | 32.3 | 420 | -0.7 | 32.1 |
| Prolactin,c ng/mL | 21 | 18.8 | 21.1 | 28 | | 10.8 | 49.4 | 30 | -6.3 | 20.8 | 340 | -0.6 | 31.2 | 419 | 0.7 | 32.0 |
| Vital signs and ECG | | | | | | | | | | | | | | | | |
| Heart rate, beats/min | 21 | -3.5 | 11.9 | 29 | | -5.8 | 10.8 | 30 | -5.3 | 12.3 | 346 | -1.4 | 12.7 | 426 | -2.1 | 12.5 |
| Systolic BP, mmHg | 21 | -2.8 | 11.3 | 29 | | 1.1 | 15.2 | 30 | -3.4 | 13.2 | 347 | -0.2 | 13.3 | 427 | -0.4 | 13.3 |
| Diastolic BP, mmHg | 21 | 0.5 | 8.7 | 29 | | 1.6 | 10.6 | 30 | -0.9 | 8.4 | 347 | 0.9 | 9.3 | 427 | 0.8 | 9.3 |
| QTcF interval, msec | 21 | 8.6 | 13.6 | 29 | | 10.0 | 21.2 | 30 | 6.4 | 15.6 | 346 | -1.4 | 21.3 | 426 | 0.4 | 20.9 |
| Extrapyramidal symptoms | | | | | | | | | | | | | | | | |
| BARS | 21 | 0.2 | 0.5 | 29 | | 0.2 | 0.9 | 30 | 0.2 | 1.6 | 347 | 0.0 | 0.6 | 427 | 0.1 | 0.8 |
| AIMS | 21 | 0.0 | 0.2 | 29 | | 0.5 | 2.4 | 30 | 0.2 | 0.6 | 347 | 0.0 | 0.9 | 427 | 0.1 | 1.0 |
| SAS | 21 | 0.3 | 1.2 | 29 | | 0.1 | 0.5 | 30 | 0.3 | 1.4 | 347 | -0.0 | 1.4 | 427 | 0.0 | 1.3 |
| a Baseline was the last non-missing measurement taken prior to start of open-label treatment (including unscheduled assessments). End of treatment includes assessments from participants who completed open-label treatment and participants who discontinued at any time during the study (based on last available assessment).  b Mean and SD calculated omitting 1 participant in the RBP-7000 90 mg group and 8 de novo participants who had least 1 erroneous measurement.  c Male and female patients combined.  AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; BMI, body mass index; BP, blood pressure; ECG, electrocardiogram; HbA1c, hemoglobin A1c; QTcF, Fridericia’s corrected QT interval; SAS, Simpson-Angus Scale; SD, standard deviation. | | | | | | | | | | | | | | | | |

**Supplemental Table 3. Mean Changes from Baseline to End of Treatmenta in Additional Safety Outcomes (Safety Population)**